Profusa, Inc. — Filing Summary
Filing identity: The supplied 10-Q is filed by NorthView Acquisition Corp., a SPAC, for the quarter ended June 30, 2023; it is not a standalone Profusa 10-Q. Profusa is the proposed merger target. The report was signed August 14, 2023.
Business context and reporting period
NorthView was formed to complete a business combination and reported no operating activity or revenue. It had entered into a merger agreement with Profusa in November 2022; if completed, Profusa would become a wholly owned subsidiary and NorthView would change its name to Profusa, Inc. NorthView remained a shell company at the filing date.
Financial results and liquidity
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | None | None |
| Formation and operating costs | $314,710 | $758,427 |
| Net income | $852,389 | $1,293,284 |
| Basic and diluted net income per share | $0.14 | $0.09 |
| Cash used in operating activities | $(1,239,875) for the six-month period |
- Net income primarily reflected non-operating trust interest and gains from revaluing warrant liabilities—not revenue from business operations. Q2 included $122,546 of trust interest and a $1,007,875 warrant fair-value gain. Six-month results included $1,964,386 of trust interest and a $433,738 warrant fair-value gain.
- Compared with the first half of 2022, six-month net income declined from $4,921,380 to $1,293,284, largely because the prior-year period included a much larger $5,172,523 warrant fair-value gain. Operating costs rose from $459,121 to $758,427.
- At June 30, 2023, cash outside the trust was $5,811; cash and marketable securities in the trust were $10,660,721. Total assets were $10,896,458, total liabilities $3,391,457, and stockholders’ deficit $2,873,934. Working capital deficit was $2,449,885.
- The sponsor convertible working-capital note had $369,589 principal outstanding and a $310,999 fair-value carrying amount. It is non-interest-bearing, due upon a business combination or liquidation, and may be converted by the sponsor into warrants.
- No long-term debt or lease obligations were reported. The company recorded an $1,848,455 excise-tax liability related to March 2023 share redemptions.
Material changes, outlook and risks
- On March 22, 2023, shareholders redeemed 18,000,868 shares for $184,845,836. The trust balance fell from $194,224,782 at December 31, 2022 to $10,660,721 at June 30, 2023. NorthView also made $194,827 in extension payments during the first half.
- The merger requires, among other conditions, at least $15 million of available cash, governmental approvals, and approval by both companies’ stockholders. The trust balance reported at quarter-end was below that minimum; the filing does not establish that the shortfall would be funded. Completion was uncertain.
- The merger agreement set Profusa’s pre-transaction equity value at $155 million, using an assumed $10 per NorthView share. Profusa stockholders could receive up to 3,875,000 additional shares subject to revenue and share-price milestones, including fiscal 2023 and 2024 revenue thresholds of $5.1 million and $73.1 million.
- NorthView had until as late as December 22, 2023 to complete a business combination, subject to possible further extension or liquidation. Management said failure to complete a transaction would require liquidation and raised substantial doubt about the company’s ability to continue as a going concern for the next 12 months.
- Management cited possible adverse effects from COVID-19 and the Russia-Ukraine war, but said their specific impact was not readily determinable. No material changes to previously disclosed risk factors were reported. Disclosure controls were assessed as effective; no material internal-control changes were reported.
Important facts for investors to verify
- Whether the merger closed, received required approvals, and satisfied its $15 million minimum available-cash condition; this filing alone does not establish the outcome.
- How the funding gap and transaction costs would be covered, given the $10.66 million trust balance and only $5,811 of unrestricted cash at quarter-end.
- The SPAC’s extension or liquidation status after December 22, 2023, and any subsequent trust withdrawals, financing, or redemptions.
- Whether Profusa achieved the merger agreement’s revenue and stock-price earnout milestones; the filing describes targets, not achieved results.
- That reported net income is driven by trust interest and volatile fair-value changes, not operating revenue, and that NorthView’s figures are not Profusa’s standalone financial results.